Meeting
2017 ASCO Annual Meeting
Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.
Authors
Hideaki Ayuhara
Tokyo Medical University Hospital, Tokyo, Japan
Hideaki Ayuhara , Daiki Tsuji , Mari Yokoi , Kenichi Suzuki , Yohei Kawasaki , Masahiko Nakao , Yuki Kogure , Kazuhiko Shibata , Toshinobu Hayashi , Keita Hirai , Kazuyuki Inoue , Toshihiro Hama , Koji Takeda , Makoto Nishio , Kunihiko Itoh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
000009335
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10091)
DOI
10.1200/JCO.2017.35.15_suppl.10091
Abstract #
10091
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
First Author: Soniya Dulal
Poster
2023 ASCO Annual Meeting
Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.
First Author: Antony Mersiades
Poster
2021 ASCO Annual Meeting
Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.
First Author: Luigi Celio
Poster
2021 ASCO Annual Meeting
Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.
First Author: Rudolph M. Navari